altretamine trade name hexalen also called hexamethylmelamine antineoplastic agent approved us fda indicated use single agent palliative treatment patients persistent recurrent ovarian cancer following firstline therapy cisplatin andor alkylating agentbased considered firstline useful salvage also advantage less toxic drugs used treating refractory ovarian precise mechanism altretamine exerts anticancer effect unknown classified mesh alkylating antineoplastic unique structure believed damage tumor cells production weakly alkylating species formaldehyde product ndemethylation administered orally altretamine extensively metabolized first pass producing primarily mono didemethylated metabolites additional demethylation reactions occur tumor cells releasing formaldehyde situ drug excreted urine carbinolamine methylol intermediates metabolism also generate electrophilic iminium species capable reacting covalently dna guanine cytosine residues well protein iminiummediated dna crosslinking dnaprotein interstrand crosslinking mediated iminium intermediate formaldehyde demonstrated although significance dna crosslinking altretamine antitumor activity side effects include nausea vomiting anemia peripheral sensory combination pyridoxine vitamin decreases neurotoxicity found reduce effectiveness altretaminecisplatin mao inhibitor cause severe orthostatic hypotension combined altretamine cimetidine increase elimination halflife httpsenwikipediaorgwikialtretamine